BioSpace News Archive

Molina Healthcare, Inc. announced details for the release of its results for the first quarter ended March 31, 2020.

Mesoblast Limited announced that the United States Food and Drug Administration has accepted for priority review the Company’s Biologics License Application filing for RYONCILTM, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease.

Bruker Corporation this week highlights new analytical systems and high-value solutions for biopharma and forensics applications, as well as for industrial process control and materials science research.

Castle Biosciences, Inc. (Nasdaq: CSTL), today announced the publication of a systematic review and meta-analysis of four study cohorts demonstrating that the DecisionDx®-Melanoma test is an independent, significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Among his many achievements, Mr. Robbins is credited with leading the highly successful U.S. launch of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in BRAF-mutant metastatic melanoma

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support the onshoring of Paratek manufacturing activities for NUZYRA.

Shimadzu Medical Systems USA, completes the integration of Core Medical Imaging Inc., a subsidiary of SMS into the company.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide progress against the company’s 2020 goals

Seneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need, announced today the appointment of Matthew W. Kalnik, Ph.D. as President and Chief Operating Officer (COO) and Dane R. Saglio as Chief Financial Officer (CFO).

Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced that Randy Shultz, Ph.D. has been promoted to the role of chief technology officer.